— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. … Read more
— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. … Read more